Sort   by:  
 Page size 
UnknownBevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
Not available
S-EPMC3732014 | biostudies-literature
UnknownOxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Not available
S-EPMC3188282 | biostudies-literature
UnknownValidation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Not available
S-EPMC3871512 | biostudies-literature
UnknownPrimary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
Not available
S-EPMC3434981 | biostudies-literature
UnknownCapecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
Not available
S-EPMC4050205 | biostudies-literature
UnknownGenetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.
Not available
S-EPMC11146432 | biostudies-literature
UnknownHIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.
Not available
S-EPMC4598284 | biostudies-literature
UnknownCOMPASS identifies T-cell subsets correlated with clinical outcomes.
Not available
S-EPMC4569006 | biostudies-literature
UnknownHLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.
Not available
S-EPMC4911012 | biostudies-literature
UnknownConsensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control.
Not available
S-EPMC8365704 | biostudies-literature
Sort   by:  
 Page size